Overview

Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

Status:
Recruiting
Trial end date:
2024-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.
Phase:
Phase 1
Details
Lead Sponsor:
BioMarin Pharmaceutical
Treatments:
Natriuretic Peptide, C-Type